biotech companies
Coverage of biotech companies in the Nexus archive.
- STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
Excluding rare disease treatments from Medicare drug-pricing pilots would eliminate significant savings, according to a Harvard University researcher. Biotech companies are lobbying the Trump administration to exclude these treatments from the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) pilots, which aim to lower drug prices to levels in other wealthy nations.
- China AI drug-design deals swell as US scrutiny mounts
Chinese AI-driven drug-design firms are securing global deals despite US scrutiny, with out-licensing deals reaching $75 billion in the first five months of 2026, up from zero before 2020.
- STAT+: Pharma goes on a spending spree, snapping up biotechs in a hurry
Pharmaceutical companies have acquired 32 biotech companies valued at $1 billion or more in the past six months, spending around $123 billion. This spending surpasses last year's totals in roughly half the time, with 26 blockbuster M&A deals in 2025 totaling $112 billion.